IPS Examines DNDi Program To Develop Pediatric HIV Drugs
Inter Press Service profiles a program launched by the Drugs for Neglected Diseases Initiative (DNDi) to develop antiretroviral drugs (ARVs) specifically designed for children living with HIV/AIDS. “The program will focus exclusively on developing child-adapted formulations for children under three, the most neglected segment in terms of availability of ARVs. The DNDi hopes to have new pediatric-specific medicines available between 2014 and 2016,” IPS writes. The article examines pediatric HIV treatment issues in India, Kenya and Brazil (Frayssinet et al., 8/29).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.